Background: From inhibiting protein function to degradation

The significance of the first U.S. Food and Drug Administration (FDA)-approved PROTAC lies in demonstrating that a protein degradation strategy can become an actual medicine, rather than in overwhelming efficacy over existing treatments. An editorial published in Nature Biotechnology on June 4, 2026, assessed the approval for a specific group of patients with breast cancer in these terms. It is a commentary examining the technology’s development and clinical limitations, rather than a research paper reporting experimental results from a new platform.

Many existing drugs bind to disease-related proteins and inhibit their function. This approach is difficult for proteins with few suitable binding sites for functional inhibition. A proteolysis-targeting chimera (PROTAC) is a bifunctional molecule that brings a target protein together with the cell’s degradation machinery. Instead of continuously blocking the protein’s activity, it marks the protein for removal.

Proposed in 2001, this strategy initially faced obstacles to clinical application because of molecular size and instability. The editorial interprets the first approval as an example showing that these development barriers can be overcome.

Key findings: ER degradation and comparison with fulvestrant

According to the editorial, the PROTAC approved in early May 2026 targets the estrogen receptor (ER). One part binds ER, while the other binds cereblon, an E3 ubiquitin ligase. When this enzyme attaches ubiquitin to the target, the proteasome—the cell’s protein degradation machinery—breaks the target down. The editorial explains that the PROTAC can detach after ubiquitin tagging and act again.

The linker joining the two binding regions is more than a simple connector. Its length, flexibility, and polarity influence the formation of a molecular arrangement suitable for ubiquitin tagging. These are design principles summarized by the editorial, rather than new computational modeling or optimization experiments performed in that article.

The editorial describes the approved population as limited to adults with ER-positive metastatic breast cancer harboring specific ESR1 mutations. These mutations are associated with resistance to first-line endocrine therapy and cause persistent ER activation. The approval does not extend to all patients with breast cancer or to proteins involved in other diseases.

The clinical trial comparator was the endocrine therapy fulvestrant. The editorial summarizes progression-free survival with the PROTAC as approximately three months longer than in the comparator group. It provides no basis for interpreting this result as an increase in overall survival. Fulvestrant also induces ER degradation, but does so by binding the receptor, destabilizing its structure, and blocking signaling. In contrast, the PROTAC recruits an E3 ligase to attach a degradation tag.

Implications and outlook: Challenges remaining after demonstrating development feasibility

The difference in mechanism did not translate into a large clinical effect. The editorial suggests that advanced tumors may use other pathways to bypass ER signaling or may survive with only a small amount of active ER as possible explanations for the limited effect. These are possible interpretations, rather than definitive conclusions explaining every patient’s treatment response. The editorial also did not assess the PROTAC as clearly superior to the best endocrine treatment options.

Other PROTACs are being developed against targets including Bruton’s tyrosine kinase (BTK), associated with blood cancers; leucine-rich repeat kinase 2 (LRRK2), associated with Parkinson’s disease; and inflammation-related targets. Molecular glues and technologies using lysosomal and autophagic pathways are also approaches to expanding the scope of targeted protein degradation. However, being in development should not be read as meaning that they are approved or have established clinical efficacy in those diseases.

Which proteins are the most suitable targets, whether PROTACs can outperform optimized inhibitors, and how broadly they can be applied remain uncertain. The first approval demonstrated the feasibility of developing PROTACs as medicines, but it does not guarantee the safe and complete removal of every target.

The approval scope and clinical figures in this article are based on the account in the Nature Biotechnology editorial Marked for destruction.